Literature DB >> 33239553

Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study.

Alessandro Maloberti1,2, Michele Bombelli2,3, Rita Facchetti2, Carlo Maria Barbagallo4, Bruno Bernardino5, Enrico Agabiti Rosei6, Edoardo Casiglia7, Arrigo Francesco Giuseppe Cicero8, Massimo Cirillo9, Pietro Cirillo10, Giovambattista Desideri5, Lanfranco D'elia11, Raffaella Dell'Oro2,3, Claudio Ferri5, Ferruccio Galletti11, Cristina Giannattasio1,2, Gesualdo Loreto10, Guido Iaccarino12, Luciano Lippa13, Francesca Mallamaci14, Stefano Masi15, Alberto Mazza16, Maria Lorenza Muiesan6, Pietro Nazzaro17, Gianfranco Parati2,18, Paolo Palatini7, Paolo Pauletto19, Roberto Pontremoli20, Fosca Quarti-Trevano2,3, Marcello Rattazzi19,21, Giulia Rivasi22, Massimo Salvetti6, Valerie Tikhonoff21, Giuliano Tocci23,24, Andrea Ungar22, Paolo Verdecchia25, Francesca Viazzi20, Massimo Volpe23,24, Agostino Virdis15, Guido Grassi2, Claudio Borghi8.   

Abstract

OBJECTIVE: Although the relationship between hyperuricemia and cardiovascular events has been extensively examined, data on the role of diuretic-related hyperuricemia are still scanty. The present study was designed to collect information on the relationship between diuretic-related hyperuricemia and cardiovascular events.
METHODS: The URic acid Right for heArt Health (URRAH) study is a nationwide, multicentre, observational cohort study involving data on individuals recruited from all the Italy territory under the patronage of the Italian Society of Hypertension with an average follow-up period of 122.3 ± 66.9 months. Patients were classified into four groups according to the diuretic use (yes vs. no) and serum uric acid (SUA) levels (higher vs. lower than the median value of 4.8 mg/dl). All-cause death, cardiovascular deaths and first cardiovascular event were considered as outcomes.
RESULTS: Seventeen thousand, seven hundred and forty-seven individuals were included in the analysis. Mean age was 57.1 ± 15.2 years, men were 45.3% and SBP and DBP amounted to 144.1 ± 24.6 and 85.2 ± 13.2 mmHg. 17.2% of individuals take diuretics of whom 58% had SUA higher than median value. Patients with hyperuricemia without diuretic use served as reference group. In multivariate adjusted analysis (sex, age, SBP, BMI, glucose, total cholesterol, and glomerular filtration rate) individuals with hyperuricemia and diuretic use exhibit a similar risk for the three outcomes as compared with the reference group.
CONCLUSION: Our study showed that diuretic-related hyperuricemia carry a similar risk of cardiovascular events and all-cause mortality when compared with individuals that present hyperuricemia in absence of diuretic therapy.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33239553     DOI: 10.1097/HJH.0000000000002600

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study.

Authors:  Min Tao; Xiaoyan Ma; Xiaoling Pi; Yingfeng Shi; Lunxian Tang; Yan Hu; Hui Chen; Xun Zhou; Lin Du; Yongbin Chi; Shougang Zhuang; Na Liu
Journal:  BMJ Open       Date:  2021-09-16       Impact factor: 3.006

2.  Cross-sectional association between gamma-glutamyl transferase and hyperuricaemia: the China Multi-Ethinic Cohort (CMEC) study.

Authors:  Yanjiao Wang; Fang Xu; Xuehui Zhang; Fei Mi; Ying Qian; Rudan Hong; Wei Zou; Hua Bai; Likun He; Songmei Wang; Jianzhong Yin
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

3.  Combined effect of hypertension and hyperuricemia on ischemic stroke in a rural Chinese population.

Authors:  Peng Sun; Mengqi Chen; Xiaofan Guo; Zhao Li; Ying Zhou; Shasha Yu; Hongmei Yang; Guozhe Sun; Liqiang Zheng; Yingxian Sun
Journal:  BMC Public Health       Date:  2021-04-23       Impact factor: 3.295

4.  Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Hangying Ying; Hongdi Yuan; Xiaomei Tang; Wenpu Guo; Ruhong Jiang; Chenyang Jiang
Journal:  Front Cardiovasc Med       Date:  2021-03-23

5.  Risk Predictors of High Uric Acid Levels Among Patients with Type-2 Diabetes.

Authors:  Zobeida Eljaaly; Muhammad Mujammami; Shaik Sarfaraz Nawaz; Mohamed Rafiullah; Khalid Siddiqui
Journal:  Diabetes Metab Syndr Obes       Date:  2021-12-24       Impact factor: 3.168

6.  Distinct Prognostic Role of Serum Uric Acid Levels for Predicting All-Cause Mortality Among Chinese Adults Aged 45~75 Years With and Without Diabetes.

Authors:  Bowen Zhu; Jian Zhang; Nana Song; Yiqin Shi; Yi Fang; Xiaoqiang Ding; Yang Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-16       Impact factor: 6.055

7.  Tea Consumption is Associated with an Increased Risk of Hyperuricemia in an Occupational Population in Guangdong, China.

Authors:  Ruining Li; Lin Zeng; Chengkai Wu; Pengcheng Ma; Hao Cui; Liya Chen; Qimei Li; Chang Hong; Li Liu; Lushan Xiao; Wenyuan Li
Journal:  Int J Gen Med       Date:  2022-03-10

8.  Prevalence and Risk Factors Associated with Hyperuricemia in the Pearl River Delta, Guangdong Province, China.

Authors:  Weiqi Liu; Weiling Liu; Shaoling Wang; Huichun Tong; Jianmin Yuan; Zhenning Zou; Jianwen Liu; Donghai Yang; Zhongxing Xie
Journal:  Risk Manag Healthc Policy       Date:  2021-02-16

9.  Medical Students' Perspective and Knowledge of Asymptomatic Hyperuricemia and Gout Management: A Cross-Sectional Study.

Authors:  Sanja Zuzic Furlan; Doris Rusic; Marko Kumric; Josko Bozic; Marino Vilovic; Tina Vilovic; Marko Rada; Venija Cerovecki; Marion Tomicic
Journal:  Healthcare (Basel)       Date:  2021-11-26

10.  Association Between Low-Dose Aspirin and Uric Acid in the Elderly: An Observational Retrospective Cross-Sectional Study.

Authors:  Jia-Run Li; Yan Fan; Mei-Lin Liu
Journal:  Int J Gen Med       Date:  2021-07-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.